

Date: 7th November, 2023

To, The Manager, Department of Corporate Services; BSE Limited P. J. Towers, Dalal Street, Fort, Mumbai – 400 001 Scrip Code:533573

The Manager, Listing Department, National Stock Exchange of India Ltd. "Exchange Plaza", Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 NSE Symbol: APLLTD

Dear Sir / Madam,

Sub: Outcome of Board Meeting

With reference to the captioned Subject, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter-alia approved the Unaudited Financial Results for the quarter and helf year ended 30th Sentember. 2023.

We enclose herewith the following:

- a) (i) Consolidated Unaudited Financial Results for the quarter and half year ended 30th September, 2023.
 - (ii) Consolidated Statement of Assets and Liabilities as at 30th September, 2023.
 - (iii) Consolidated Cash Flow Statement for the half year ended 30th September, 2023.
- b) (i) Standalone Unaudited Financial Results for the quarter and half year ended 30th September, 2023.
 - (ii) Standalone Statement of Assets and Liabilities as at 30th September, 2023.
 - (iii) Standalone Cash Flow Statement for the half year ended 30th September, 2023.
- Limited Review Report by Statutory Auditors on the Consolidated and Standalone Unaudited Financial Results.

The time of commencement of the Board Meeting was 11:30 a.m. and the time of conclusion was 1:25 p.m.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Alembic Pharmaceuticals Limited

nisha Saraf Company Secretary

Encl.: A/a.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 350 003. * TEL : (0265) 2380559, 2380569. * FAX : (0265) 2281225 website : www.alembiopharmaceuticals.com * E-mail : alembic @alembic.co.in * CIN : L24236L2019ELC061123



ALEMBEC PHAGMACEUTICALS LIMITED CIN12A230030300,0001123 Pagd. Office: Alembic Road, Vedodare - 300 003 Tel : ELSS 2200550 Email : apLinestondbalentbic.co.in Vedodar : www.aleedalgalantacau.doalc.com

Statement of Consolidated Unaudited Pinancial Results for the quarter and half year ended 30th September, 2023

			Quarter Ended		Half Yea	Pa. in Cross Year Ended	
	" Particulara	30.09.2023 (Unsudited)	30.05.2023 (Unaudited)	30.09.2022 (Unsudited)	30.09.2923 (Unsudited)	30.09.2022 (Unsedited)	31.03.2023 (Audited)
1	Revenue from Operations	1,594.93	1,405.15	1,475.01	3,051.05	2,737.15	5,652.62
2	Other Income	50.15	11.67	0.33	21.02	1.41	2.74
3	Total Bocome	1,605.08	1,497.81	1,475.34	3,102.90	2,736.57	5,655.36
4	Experses .		11.000	2001.223		1000	
	(a) Cost of Materials consumed	413.87	334.19	343.71	748.06	606.72	1,250.00
	(b) Purchase of stack-in-trade	88.48	90.24	113.60	178.92	218.46	360.09
	(c) Changes in Inventories of finished goods, Stock in trade and WIP	(41.12)	(10.91)	(14.28)	(\$2.02)	(5-88)	78.65
	(d) Employee benefits expense	346.99	348.17	299.79	655.16	580.20	1,169.13
	(e) Finance Costs	15.09	14.39	12.41	30.05	21.20	50.17
	(f) Depreciation & Amortization Depense	67.56	66.10	67.30	133.74	134.00	275.43
	(g) Other Expenses	\$78.26	\$35.77	\$29.44	1,104.03	1,009.25	2,066.33
	Total Esperana	1,469.94	1.368.03	1,322.38	2,837.96	2,645.76	5,269,86
8	Profit before Share of Profit / (Loss) of Associates and Jaint Vestures	138-15	129.79	152.56	264.93	92.80	385.50
	Share of Profit / (Loss) of Associates & Joint Ventures	(0.53)	(0.03)	(1.65)	(0.54)	(8.87)	(30.92
,	Profit Before Exceptional Item and Tax	134.64	129.76	151.31	264.40	83.93	354.59
	Exceptional Item (Net of Tax) - Refer Note No 5						
	Profit Before Tax	134.64	129.76	151.31	264.40	83.93	354.55
10	Tax Expense				1.		
	(i) Current Tax	3.54	4.29	23.66	7.84	25.14	4.20
	(ii) Deferred Tax	(5.46)	4.05	(5.90)	(0.60)	(0.68)	9.20
	(III) Short ((Excess) Tax Provision				•		(0.79
11	Profit for the Parkod	136.56	120.60	133.35	257.16	62.42	341.99
12	Other Comprehensive Income						
	A 00 Terms that will not be reclassified to profit / (loss)	(2.01)	(0.09)	1.09	(2.10)	0.13	(0.35
	 [1] Income tax relating to items that will not be reclassified to profit / (loss) 			(0.02)		(0.02)	
	(0 Iterus that will be reclassified to profit / (loss)	2.50	(0.85)	5.15	1.73	11.42	13.71
	Total Other Comprehensive Income (A+8)	0.57	(0.94)	6.22	(0.37)	11.52	13.37
13	Total Comprehensive Income for the period (11+12)	137.12	119.66	139.57	256.79	78.59	355.36
14	Barnings per share - Basic & Diluted (in Rs.)	6.95	6.34	6.78	13.08	3.43	17.40
18	Poid up Equity Share Capital (Face Value of Rs 2/- each)	39.31	39.31	39.31	29.31	29.31	39.35
16	Other Eaulty		1.11		10000		4,331,35





Notes :

- The above consolidated results, have been reviewed by the Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors of the Company.
- 2 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment.
- 3 As informed to Stock Donharging orders, the Company received a letter from Stock Donharging returning the drift scheme of temperature of general survey as approved by the Decent of Directory at its meeting held on 24M Merch 2823. The Company directed of the Danhelders of the Instance of a scheme of the Scheme of Schem
- 4 As already leftering to the stock exchange, due to flash floads in river. Testis because of cload barst, guider with alum end much estimated are manufacturing bardlars at here. Testis because of a real bardlars and the set manufacturing approximate proceedings of the stock of bardlars, 2017. There is no laws of the program of the stock of the stock
- 5 During the Hwinh 2020 quarter, the Conserve head charged off its 1025 K6 corress (red if defended that if ks. 126-77 corress) as privations for impairment of assorbering that impaired assorbering to identificit quark in other repressions (2017), and the conserved resorber with the present encourse the transmitter from the present encourse that the statement of privit and toxis and shows and shows and exceptional frame. Occ of anywates are ready, the conserver, in respect of membratisming frame and the statement of privit and toxis and shows and shows and exceptional frame. Occ of anywates are ready, the conserver, in respect of membratisming frame and the statement of privit and toxis and shows and exceptional frame. The conserver is the statement of privit and the conserver is the statement of the statement of privit and the conserver is the statement of the statement of privit and the statement of privit.
- 6 Additional information to investors are provided hereunder:

Perticulara		Half Yo	Typer Ended			
Particulars	30.09.2023	33.06.2623	10.09.2022	30.09.2121	30.09.2022	31.03.2023
Research and Development Expenses	121.13	118.59	167.65	239.72	428.70	721.84

The previous year's corresponding quarter, hell year and annual numbers are not comparable as it includes NIO expenses of Ro. 16.16. Crores, Ro 130.85 covers and Ro 155.33 Dovers respectively charged to the statement of prefit and loss account (RBD development expenses (intangible assets) in ensolvible dears Democratical Limited).

Disclosures as per Regulation 52(4) of the SDDI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as applicable and additional informations are given hereunder:

57.	Particulars	Quarter Ended			Half Yea	Year Ended	
60		30.09.2023	30.06.2023	30.09.2022	30.09.2023	30.09.2022	31.03.2023
a	Debt-Equity Ratio (in times)	0.18	0.18	0.14	0.18	0.14	0.15
	Debt / Net Worth (Debt : Total Debt (Short term + Long term) Net worth : Share Capital + Other Equity)						
6	Debt Service Coverage Ratio (in times) # (Profit before tex+interest) / (Interest + schedule principal repeyments of Long term debt) Annualised	9.58	10.02	14.49	9.79	1.93	2.23
¢	Interest Service Coverage Ratio (in times) # (Profit before tax+interest)/ interest	9.58	10.02	16.49	9.79	10.57	10.91
d	Not Worth (Rs. in Crores)	4,469,44	4.489.55	5.119.66	4.469.44	5.119.66	4,369.90
•	Current Ratio (in times)	1.73	1.77	1.50	1.73	1.56	1.76
	Current Asset / Current LiebEltios						
r	Bad Debts to Accounts Receivable Ratio (%) Rad Debts / Accounts Receivable	0.06%	0.02%		0.06%		0.61%
7	Current Liability Ratio (in times) Current Liabilities / Total Liabilities	0.91	0.92	0.92	0.91	0.92	0.90
h	Total Debts to Total Assets (in times)	0.13	0.11	0.11	0.13	0.11	0.12
	(Long term Borrowings + Short Term Borrowings+ Lease Hability)/ Total Assets						
ł	Debtors Turnover Ratio (in times) (Value of Sales and Service / Average Debtor) Armeitsed	5.96	5.69	7.10	5.76	6.59	6.06
	(value or sales and service) Average Debter) Armonises						
5	Investory Turnover (in times)	6.20	5.98	5.50	6.07	5.11	5.49
	(Sale of products / Average WIP, FG and Stack in trade Stventory) Annualised						
k	Operating Margin (%) #	13,46%	14.15%	15,02%	13,99%	12.36%	13.77%
	EBITDA / Revenue from Operations				11-12-0		
1	Net Profit Hargin (%) #	8.56%	8.11%	9.44%	8.35%	6.41%	8.79%
	(Net Profit after taxes and share of Profit/(Loss) of Associates and Joint Ventures)/ Revenue from Operations					1.5	
•	Earnings per share (in Rs.)#	6.93	6.14	7.01	13.08	8.93	25.29

Ratias are calculated before non-cash non-recurring R&D expenses as mentioned in Note No. 6

The previous quarter's / year's figures have been represed / reamanged wherever necessary to make it comparable with the current quarter / year.





Place : Panelov Date | 7th November, 2023

Particulara	As at 30th September, 2023	Rs. in Cros As at 31st March, 2023	
	(Unaudited)	(Audited)	
ASSETS			
1 Non-current assets			
(a) Property, plant and equipment	2.602.70	2,398.4	
(b) Capital work-in-progress	470 12	601.2	
(c) Financial Assets			
(i) Investments	23.04	71.2	
(ii) Investment accounted for using Equity Method	24.77	25.1	
(d) Deferred tax assets (ret)	123.70	123.0	
(e) Other non-current assets	18.80	53.2	
(c) one not cannot asses	10,00	50.1	
2 Current assets			
(a) Inventories	1,539.24	1,475.2	
(b) Financial Assets			
Trade receivables	1.075.07	1.046.4	
- Cash and cash equivalents	141.30	75.4	
 Bank balances other than cash and cash equivalents 	6,50	6.7	
- Other financial assets	10.72	9.8	
(c) Current Tax Assets (Net)	72,43	82.7	
(d) Other current assets	288.87	213.5	
TOTAL - ASSETS	6,455.27	6,182.8	
B EQUITY AND LIABILITIES			
1 Baulty	A COLORADO D		
(a) Equity Share capital	39.31	39.3	
(b) Other Equity	4,430.70	4,331.1	
2 Non-current liabilities			
(a) Financial liabilities			
- Lease labilities	67.41	69.2	
(b) Provisions	107.93	105.2	
3 Current liabilities			
(a) Pinancial liabilities			
- Borrowings	784.38	635.8	
- Lease liabilities	16.95	16.9	
- Trade payables			
A) Due to Micro and Small Enterprises	18.65	23.1	
D) Due to other than Micro and Small Enterprises.	743.10	656.6	
	104.26	148.7	
Other financial liabilities			
(b) Other current liabilities	76.00	85.5	
	76.80 65.54	20.0	



For Alembic Pharmaceuticals Limited

Augura An

Place : Panelav Date : 7th November, 2023

Consolidated Statement of Cash Flows for the half year ended 39th September, 2023

*articulars	For the Half Year ended 30th September, 2023	ended 300 September, 202
A CASH FLOWS FROM OPERATING ACTIVITIES:	(Unsudited)	(Uneedited
Net Profit Before Tax as ser Statement of Profit and Loss (After Exceptional Item and Tax thereas)	264.40	41.91
Adjustments for:	264.40	63.93
Share of (Pfofit) / Loss of Associates and Joint Ventures	0.54	8.07
Depreciation and emortiation	133.74	134.00
Interest Depense	30.05	21.20
Interest Income	(1.05)	(0.04
Dividend Income / Gein on Sale of Investments	(0.70)	(0.24
Unrealized foreign exchange (gain) / loss (not)	(35.26)	31.10
Fair value (gain)/ loss on financial instruments at fair value through profit or loss	(1.04)	(0.07
Provision / write off for doubtful trade receivables	0.26	
Sundry balances written off / written-back (net)	(0.01)	0.03
Loss/(Prafit) as sale of Asset	(2.33)	0.03
Fraduct development expenses		\$8.44
Operating Profit before change in working capital	387.01	178.05
Working capital changes:		
[Increase]/Decrease in Inventaries	(63.98)	21.39
(Increase) in Trade Receivables	(9.30)	(7.68
(Increase)/Decrease In Other Assets	(73.29)	59.88
Increase/(Decrease) In Trade Payables	62.00	31.00
Increase/(Decrease) In Other Liebilities	(27.03)	(48.45
Increase/(Decrease) in Provisions Cesh generated from operations	(4.65) 299.54	11.07
Direct laxes (paid) / refunds (Net)	2.47	(31.03
Net Cash inflow from Operating Activities (A)	293.01	414.24
B CASH PLOWS PROM INVESTING ACTIVITIES:		
Proceeds from Sale of Asset	11.40	0.00
Enterest received	1.05	0.04
Dividend / Gain on Sale of Investments received	0.70	0.24
Purchase of Property, Plent & Equipments, Intangible Assets and Capital Advance	(109.39)	(234.31
Investment in Alternative Investment, Bouly Fund Net Cash influer from Investing Activities (B)	(175.43)	(7.00
CASH FLOWS FROM FINANCING ACTIVITIES		(144.00
Repayment of borrowings		(200.00
Net Increase / (Decrease) in short term borrowings	145.51	263.39
Payment of lease kabilities	(13.60)	(9.92
Change in Restricted Back Balances other than Cash & Cash Equivalents	(0.01)	1.52
Dividends paid Interest and other finance casts (including barrowing cast capitolised)	(157.25)	(194.56
Interest and other financie costs (including barrowing cost capitolised) Net Cash inflow from Financing Activities (C)	(29.41) (51.76)	(27.39
Net (Decrease)/Increase in cash and cash equivalents (A+B+C)	65.82	4.31
E. a) Cash and cash equivalents at the beginning of the Year	75.48	61.09
b) Effect of exchange differences on restatement of foneign currency cash and cash equivalents		0.00
 Cash and cash equivalents at the end of the period (1+13) 	141.30	65.40
 Cash and cash equivalents at the end of the period 		
Belences with Banks Cash on band	140.95	65.20 0.20
Cash and cash equivalents	141.30	65.40
	141.30	60.40
(ruhate to)		naceuticals Limited
C INFORMATION	3/ 151 -	
The second se	WADCOARA OP	-

Chirayu Amin Chairman and CEO

Flace : Panelev Date : 7th November, 2023 Volt us at www.alembiopharmacouticals.com



ALEMBIC PHARMACEUTICALS LIMITED CIN: 124230538609L0051123 Forgl. Office: Alembic: Read, Vedodera 390 003 Tel: 0285 2285590 Tel: 0285 2285590 Hebsite: www.alembicpharmaceuticals.com

Statement of Standalone Unaudited Pinancial Results for the quarter and half year ended 30th September, 2023

		Quarter Ended			Half Yea	Fis. in Crore Year Ended	
	* Particulars	30.09.2023 (Unsudited)	30.66.2023 (Unsudited)	30.09.2022 (Unaudited)	30.09.2023 (Unsudited)	30.09.2022 (Unaudited)	31.03.2023 (Audited)
1	Revenue from Operations	1,478.84	1,332.27	1,354.42	2,811.11	2,531.67	5,149.00
2	Other Income	8.95	11.54	0.47	20.89	1.00	3.55
3	Total Income	1,467.79	1,344.12	1,354.88	2,631.91	2,532.67	5,152.54
4	Exponses.	1000			1.1.1.1		
	(a) Cost of Materials consumed	413.87	334.19	343.71	748.05	608.72	1,250.00
	(8) Purchase of stock-in-trade	85.65	89.95	95.09	178.63	185.45	337.21
	(c) Changes in Inventories of finished goods, Stock in trade and supp	(30.07)	(7.20)	(16.99)	(37.27)	12.49	72.84
	(d) Employee benefits expense	326.41	327.47	257.60	453.07	534.39	1,094.82
	(a) Finance Casts	15.39	14.29	11.96	29.68	20.75	49.00
	(f) Depreciation & Amortization Expense	67.18	65.75	65.80	132.94	133.56	272.95
	(g) Other Expenses	475.50	422.13	419.43	897.63	919.70	1,729.73
_	Total Expenses	1,353.95	1,246.59	1,187.88	2,603.54	2,415.06	4,805.63
5	Profit Before Exceptional Item and Tax	133.64	97.53	167.00	231.37	117.61	345.93
6	Exceptional Item (Net of Tax) - Refer Note No 4						
7	Profit Before Tax	133.84	97.53	167.00	231.37	117.61	345.92
8	Tax Expense						
	00 Ouwers Tax			20.56		20.56	
	(ii) Short /(Excess) Tax Provision		100				(0.75
9	Profit for the Period	133.64	97.53	545.44	231.37	97.05	346.73
10	Other Comprehensive Income	265					
	(i) Demo that will not be reclassified to profit / (loss)	(2.01)	(0.09)	1.09	(2.10)	0.13	(0.35
	 (ii) Income tax relating to items that will not be reclassified to profit / (kss) 	•		(0.02)		(0.02)	
11	Total Comprehensive Income for the period	131.43	97.44	147.51	229.27	97.15	345.3
12	Cernings per share - Dasic & Diluted (in Ra.)	6.01	4.96	7.45	11.77	4.94	17.6
13	Peld up Douity Share Capital (Face Value of Ra 2/- each)	39.31	39.35	39.31	29.31	29.31	29.3:
14	Other Douity		2000	2.0 /3			4,374,99





Notes :

- The above standatone results, have been reviewed by the Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors of the Company.
- At Internet to Stock Durburges earlier, the Company: received a latter from Stock Durburges instanting the data betweet of enrepresentation of present inserve approach by the bisched Durburges and the standard barry. The Company: excluded end to approach the relation of European and the Barry, 2023. The Company is discussed and the standard barry and the available for distribution and environment. The Standard Barry and Standard Barry and Standard Barry and the standard Barry and Standard Barry Standard Barry and Stan
- An already informed to the stock exchanges, due to fash floods in river Tessia because of cloud burst, water with sight end invol estendi or manufacturing facility at Norminas, South Sakim and homon meanteduring operatives atond dampede w.a.f. 4th October, 2023. There is no loss of them expectives. The assessment of loss(damage in under programs. At assess of the Company are adequated insured in theorem) instruments.
- 4 During the Nameh 2023 passes, the Company last damped of the 155556 come (out of element use of the 124.77 covers) is provision for investment of its setting that and the setting of the 155556 come (out of element of the 155556 come) and the 155556 come of the 155556 come o
- 5 Additional information to investors are provided hereunder:

Particulars		Quarter Ended		Half Ye	Year Ended	
Parocatan	30.09.2023	30.06.2023	30.09.2022	30.09.2023	30.09.2522	31.43.2023
Research and Development Expenses	120.70	117.75	162.06	235.45	414.88	609.33

The previous year's corresponding querter, helf year and annual numbers are not comparable as it includes MAD expenses of Rs. 16.16. Crees, Rs 130.85 crees and Rs 155.13 crees respectively charged to the statement of profit and loss account (NBD development expenses (stangible assets) in entrabile Alex Dermanuticals Limited).

6 Disclosures as per Regulation 52(4) of the SEBJ (Listing Obligations and Disclosure Requirements) Regulations, 2015 as applicable and additional informations are given hereinder:

Sr.	Particulara	Quarter Ended			Balf Yol	Year Ended	
No		30.09.2023	30.05.2023	30.09.2022	30.09.2023	30.69.2022	31.03.2023
	Debt-Equity Ratio (in times)	9,17	0.13	0.13	0.17	0.13	0.54
	Debt / Net Worth (Debt : Tetal Debt : Short term + Long term) Net worth : Share Capital + Other Equity) Debt Service Coverage Ratio (in times) = (Insits befare tax+interest) / (Inserest + schedule principal reasyments of Long term debt) denaulised	9.70	7.82	16.31	8.89	2.21	2.20
¢	Interest Service Coverage Ratio (in times) # (Profit Defare tox+interest)/ interest	9.70	7.82	16.31	6.00	12.30	10.97
	Net Worth (Rs. in Crores)	4,485,74	4,511,17	5,192.62	4,485.74	5,193.62	4,413.72
e	Current Ratio (in times)	1.74	1.75	1.62	1.74	1.62	1.79
	Current Asset / Current Liabilities						
	Bad Debts to Accounts Receivable Ratio (%) Red Debts/ Accounts Receivable	0.06%			0.06%		0.03%
0	Current Liability Ratio (in times) Current Liabilities / Total Liabilities	0.91	0.92	0.89	0.91	0.69	0.90
h	Total Debts to Total Assets (in times) (Long term Barrowings + Short Term Borrowings+ Lease	0.13	0.11	0.11	0.13	0.11	0.12
ł	Tability// Total Assets Debters Turnover Ratio (In times) (Value of Sales and Service / Average Debter) Annualised	4.95	4.48	5.20	4.62	4.93	4.67
1	Inventory Turnsver (in times)	7.32	6.23	6.32	6.16	5.92	6.24
k	(Sale of products / Average WIP, FG and Stock in trade (reventory) Annualised Operating Margin (%) #	14.63%	13.33%	18.15%	14.02%	14.63%	14.88%
	EBITDA / Revenue from Operations						
ľ	Net Profit Margin (%) # Net Profit after taxes / Revenue from Operations	9.05%	7.32%	11.25%	8.23%	8.30%	9.75%
-	Familians per share (in Bs.)#	6.01	4.04	2.25	11.77	10.43	25.53

Ratios are calculated before non-cash non-recurring RSD expenses as mentioned in Note No. 5

The previous quarter's / year's figures have been regrouped / rearranged whereiver necessary to make it concereble with the current quarter / year.



Chiragu Amin Chiragu Amin Chiragu Amin Chiragu Amin Chiragu Amin

Place : Panelav Date : 7th November, 2023

	Particulars	As at 30th September, 2023	As at 31st March, 2023
		(Unaudited)	(Audibed)
	ASSETS		
1	Non-current assets		
	(a) Property, plant and equipment	2,590.94	2,377.4
	(b) Capital work-in-progress	478.12	601.2
	(c) Financial Assets		
	(i) Investments	231.11	229.2
	(#) Loan	10.76	10.3
	(d) Deferred tax assets (net)	78.16	78.1
	(e) Other non-current assets	18.80	53.3
2	Current assets		
	(a) Inventories	1,324.46	1,275.1
	(b) Financial Assets		
	- Trade receivables	1,209.06	1,201.2
	- Cash and cash equivalents	54.64	21.0
	- Bank balances other than cash and cash equivalents	6.50	6.3
	- Others financial assets	10.29	9.1
	(c) Current Tax Assets (Net)	71.42	76.3
	(d) Other current assets	252.50	189.
	TOTAL - ASSETS	6,336.77	6,130.4
8	EQUITY AND LIABILITIES		
1			
۰.	(a) Equity Share capital	39.31	39.5
	(b) Other Equity	4,447.00	4,374,5
2	Non-current liabilities		
	(a) Financial Ilabilities		
	Lease liabilities	57.00	58.6
	(b) Provisions	107.93	105.
3	Current liabilities		
	(a) Financial Rabilities		
	- Borrowings	780.00	635.0
	- Lease Rabilities	16.23	16.3
	- Trade payables		
	A) Due to Micro and Small Enterprises	18.85	23.
	B) Due to other than Micro and Small Enterprises	624.16	572.3
	- Other financial liabilities	104.19	145.3
	(b) Other current liabilities	76.77	85.4
	(c) Provisions	65.32	69.5

Place : Panelav Date : 7th November, 2023



For Alembic Pharmaceuticals Limited

Chirayu Amin

Standalone Statement of Cash Flows for the half year ended 30th September, 2023

	For the Half Year	For the Half Yea
articulars	For the Half Year ended 30th	For the Half Tea ended 30t
arriver and a second	September, 2023	September, 202
	(Unsudited)	Unaudited
CASH FLOWS FROM OPERATING ACTIVITIES:	(chiothio)	LO HELDING
Net Prefit Before Tax as per Statement of Profit and Loss (After Exceptional item and Tax thereon)	231.37	117.61
Adjustments for:		
Decreciation and amortination	132.94	133.56
Interest Expense	29.60	20.75
Internal Income	(2.21)	(0.18
Dividend Income / Gain on Sale of Investments	(0.70)	(0.24
Unrealized foreign exchange (gain) / loss (net)	(35.26)	31.10
Fair value (gain)/ loss on financial instruments at fair value through profit or loss	(1.64)	(0.07
Provision / write off for doubtful trade receivables	0.26	
Sundry belances written off / written-back (net)	(0.01)	0.0
Loss/(Profit) on sale of Asset	(0.06)	0.0
Product development expenses	(4144)	98.44
Operating Profit before change in working capital	354.16	401.04
		401.0
Working capital changes:		
(Increase)/Decrease In Inventories	(49.23)	39.9
(Increase)/Decrease In Trade Receivables	7.74	(39.8
(Increase)/Decrease In Other Assets	(61.13)	55.4
Increase In Trade Payables	47.81	19.4
Increase/(Decrease) In Other Liabilities	(27.84)	(41.4
Increase/(Decrease) In Provisions	(5.00)	11.03
Cash concrated from operations	266.40	438.9
Direct taxees (could) / refunds (Net)	5.78	(31.2
Net Cash inflow from Operating Activities (A)	271.68	407.6
8 CASH FLOWS FROM INVESTING ACTIVITIES:		
Proceeds from Sale of Asset	0.05	0.0
Loan to subsidiary company (Net)	0.00	(7.9)
Loan to subsidiary company (Net) Interest received	1.85	0.0
Dividend / Gain on Sale of Investments received	0.70	0.2
Purchase of Property. Plant & Equipment and Capital Advance	(187.51)	(233.7
		(2.58.7
Investment in Alternative Investment Equity Fund	(184.88)	
Investment in Alternative Investment Equity Fund Net Cash Inflow from Investing Activities (B)	(184.88)	(250.64
Investment in Alternative Investment Equity Fund Net Cash Inflow from Investing Activities (B)	(184.88)	(250.6
Investment in Alternative Investment Equity Fund Net Cash Inflow from Investing Activities (B)	(184.88)	
Investment in Alternative Investment Explor Fund Net Cash Inflow from Investing Activities (8) CASH FLOWS FROM FINANCING ACTIVITIES:	(184.38)	(200.0 263.3
Investment in Nationable Operations (Spain Fund Nei Cauh Inflow from Jonashing Activities (D) CC CASH FLOWS FROM FINANCING ACTIVITIES: Responsed to Increasing		(200.0 263.3
Investment in Attentione Enversione Explore fund Net Canih Inter Mer Dimateling Activities (\$) C CASH FLOWS FROM FINANCING ACTIVITIES: Responses of bornwidge Ref (crosses / Operate) in writing capital dereard borns	144.93	(200.0 263.3 (9.9
Similar La Alternative Environis Guart (Indi And Cash Informative Monositing Activities (E) 5 CASH Floores Floor (FRANCERA CATUTTE: Regrammat of Environistics Reg (Incesser / Obscience) in which are certed and there Provide in Reg (Incesser) in Anticol Cash Cash Reg (Individents Decesser in Regramed) Biola Malances certe much and Cash Registerist	144.93 (12.04)	(200.0 263.3 (9.9 1.5
Investment in Attentione Investment (6 (stup): faid Atten Calm Horts from Foreasting Activities (6) C CASH FLOWS FROM TRANSCING ACTIVITIES: Regenerate at Intermediage Ref (conset) (Consect)) (marking capital deteards laters for factorises (Consect)) (marking capital deteards laters for the intermediage laters (consect) (consect) (consect) For the intermediage laters (consect) (consect) (consect) (consect) For the intermediage laters (consect) (consect) (consect) (consect) For the intermediage laters (consect) (cons	144.93 (12.04) (0.01)	(200.0 263.3 (9.9 1.5 (196.5
Interpretent in Materialize Developments Sparty fixed Materials Information Management (State State C ASH FLOORS FROM TRANCERGE ACTIVITIES: Respenses al Interpretent Res (Docesser / Discoverse) in weaking capital development from Thomas in Respension Mailwares and that cach A Cach Responses Thomas in Responses	144.93 (12.04) (0.01) (157.35)	(200.0 263.3 (9.9 1.5 (196.5 (27.3
burdense in Atteriories Juscimier Grupping Cala Andre Marken March March (1994) Cala Andre Marken March (1994) Cala Andre Marken March (1994) Andre March (1994) Andre March (1994) Andre March (1994) Andre Marken Marken Statut (1994) Andre Marken Marken Marken Statut (1994) Andre Marken Marken Marken Marken (1994) Andre Marken	144.33 (12.04) (0.01) (157.35) (23.45)	(200.0 263.3 (9.9 1.5 (196.5 (27.3 (166.9
Institutes in Administration (Sarah Sarah	144.33 (12.04) (0.01) (157.35) (23.43) (53.43) 33.97	(200.0 263.3 (9.9 1.5 (196.5 (27.3 (166.9 (11.9
Interstein nichtenber bereiheit (syn hul Recht ander unter bereiheit (syn hul Recht ander unter bereiheit (seinten) (s. 1) C. dari Konsteller (Sternetzen) (s. 1) Regenstell allennengen Der songen ist einer songen (s. 1) Recht ander Sternetzen	144.93 (12.04) (0.01) (157.25) (29.45) (53.83)	(200.0 265.3 (9.9 1.5 (196.5 (27.3 (160.9 (11.9 (11.9 (11.9)))))))))))))))))))))))))))))))))))
Instantiant in exhibition (Eggin Aria) Call Call Andre Versi Warrel Andrea, Kalling (Maria) Call Call Call Call Call Call Call Call	144,93 (12,44) (0,61) (157,25) (29,45) (53,43) 33,97 21,67	(200.0 263.3 (9.9 1.5 (166.5 (166.5 (166.9 (11.9 (11.9 11.5 0.0
Intersection induced between the provide Card and work was been backed as CTTESS Card and work was been backed as CTTESS Card and work was been backed as CTTESS Backed and the second as a construction of the interprovide and the second as a construction of the interprovide and the second as a construction of the Card and work was many second as a construction of the Card and work was many second as a construction of the Card and work was many second as a construction of the Card and work was many second as a construction of the Card and work was many second as a construction of the Card and work was many second as a construction of the Card and work was many second as a construction of the Card and work was many second of the provide of the Second as a construction of the second of the provide of the Card and and was many second of the provide of the Second as a construction of the second of the provide of the Second as a construction of the second of the provide of the Second as a construction of the second of the provide of the Second as a construction of the second of the provide of the Second as a construction of the second of the provide of the Second as a construction of the second of the provide of the Second as a construction of the second of the provide of the second of the secon	144.33 (12.04) (0.01) (157.35) (23.43) (53.43) 33.97	(200.0 263.3 (9.9 1.5 (166.5 (166.5 (166.9 (11.9 (11.9 11.5 0.0
The strength of the strength o	144.93 (1284) (0.01) (157.35) (23.45) (23.45) (23.45) (23.45) (23.45) (21.67 21.67	(200.0 263.2 19.5 (196.5 (196.5 (127.3 (106.9 (11.9 (11.9 11.5 0.0 1.5
memorane in advanced to the topological space of the second space	144.93 (12.84) (0.81) (15.7.35) (12.45) (12.45) 22.47 21.67 54.64 54.84	(200.0 263.3 196. 1.5 (166.9 (166.9 (166.9 (11.9 11.5 0.0 1.5
The strength of the strength o	144.93 (1284) (0.01) (157.35) (23.45) (23.45) (23.45) (23.45) (23.45) (21.67 21.67	(250.46 (260.00 265.35 (1965.26 (1965.26 (1965.26 (1965.26 (1965.26 (1965.26 (1965.26 (1965.26 (1965.26)(1965.2

Visit us at w

sta cos

Mace : Panelav Date : 7th November, 2023 For Alembic Pharmaceuticals Limited

Chiragu Amin Chairman and CEO INDEPENDENT AUDITORS' REVIEW REPORT ON THE CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2023

K C Mehta & Co up

To, The Board of Directors Alembic Pharmaceuticals Limited

- We have reviewed the accompanying Statement of Consolitated Unsudted Financial Results of Alembite Pharmaceutical Emitted¹ (*h Holding Company)² and its subsidiaries (the Holding Company and its subsidiaries collectively referred as "the Group"), and its share of the net portifi (tiss) after tax and the total comprehensive income of its socialized for the augret run and hily are ended September 39, 2023 (Herina fater reference to as "the Statement"), being submitted by the Holding Company pursuant to the requirements of Regulation 33 and Regulation 32 of the SER (Listice Oblicions and Disclover Requirements) Resultation, 2015, as amended.
- This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 Interim Financial Reporting' ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility to express a conduction on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRI) 2410 Review of Interim Financial Information Performed by the Independent Avalitor of the First¹, Suiced by the Institute of Duratered Accountants of India. A review of Interim Financial Information consists of making Inquiries, primary of performs responsible for financial and accounting matters, and adopting antifylical and Statistical Constraints of India. A review of Interim Financial Information constitution Statistical Constraints of India. A review of Interim Financial Information Constitution Statistical Constraints of India (India Constraints) and India (India Constitution). Statistical Constraints of India (India Constraints) and India (India Constraints).

We also performed procedures in accordance with the Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the SEB (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.

- 4. The Statement includes the results of the entities as mentioned under Annexure 1.
- 5. Based on our review conducted and procedures performed as stated in paragraph 3 allow and based on the consideration of the review report of other auditor referred to a paragraph 6 bale, which has come too average the state of the st



Converse isso Lankol Linkiny Parmersky (LLFN: Alik-Ar71) w. s. f. Jane 3, 2022 from K. Olohan 6. G. Illers Reg. Mov. (U)/03310961 Regid Office: Meghdhanush, Raro Courso, Vudodara - 390 007 | Branches: Ahmedabod - Stengahuru - Mumhai Phone: +91 2 652 444000 | e-mail: connectsfiktembhar.com | website: www.kkmehhar.com

Other Matters

 We did not review the interim financial results of 1 subsidiary as mentioned in paragraph 4 above included in the consolitated unautided financial results, whose interim financial results for the quarter and half year ended September 30, 2023 reflect as follows:

K C Mehta & Co up

Particulars	Quarter ended September 30, 2023	Half year ended September 30, 2023
Total Assets	1,190.85	1,190.85
Total Revenues	392.85	779.63
Total Net profit/(loss) after tax	8.99	20.03
Total Comprehensive Income	11.27	22.02
Total Cash Inflow/(Outflow) (net)	4.49	27.59

These interim financial results have been reviewed by other auditor whose report has been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosure included in respect of the said subsidiary it based solely on the report of the other auditor and procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

7. The consolidated unsadiated financial results include the interim financial information of 2 subsidiaries for the quarter and half year ended September 30, 2023 as reflected in the table below, which have not been releviewed/audited by their auditors and are as prepared by the management. According to the information and explanations given to us by the management, the interim financial information of these 2 subsidiaries is not material to the forup.

		In Crore
Particulars	Quarter ended September 30, 2023	Half year ended September 30, 2023
Total Assets	71.54	71.54
Total Revenues	28.48	36.44
Total net profit/(loss) after tax	4.32	(0.77)
Total Comprehensive Income	4.63	(1.02)
Total Cash Inflow/(Outflow) (net)	6.47	5.25

Our conclusion on the Statement is not modified in respect of the above matter.



8. The consolidated unaudited financial results also include the Group's share of net profit after tax, and total comprehensive income for the quarter and half year ended September 30, 2023 as mentioned below, in respect of 1 associate based on its interim financial results which have not been reviewed/audited by its auditors. According to the information and explanations given to us by the Management, the interim financial information of an associate is not material to the Group and are as greated by the management:

K C Mehta & Co LLP

Particulars	Quarter ended September 30, 2023	Half year ended September 30, 2023
Total net profit/(loss) after tax	0.13	0.20
Total Comprehensive Income	0.13	0.20

Our conclusion on the Statement is not modified in respect of the above matter.

For K C Mehta & Co LLP Chartered Accountants Firm's Registration No. 106237W/W100829

Milin Mehta Partner Membership No. 038665 UDIN: 230386655BHBXDB8453 Place: Vadodara Date: November 7, 2023



Annexure - 1

Details of entities included in Consolidated unaudited financial results of the Alembic Pharmaceuticals Limited: For the Quarter and Half year ended September 30, 2023

K C Mehta & Co LLP

Sr. No.	Name of Entity Alembic Pharmaceutical Inc.		Relation	Consolidated /Standalone	Included in consolidation	Whether reviewed by other auditors
1			Subsidiary	Consolidated	Yes	Yes
	a.	Okner Realty LLC	Step down subsidiary			
	b.	Alembic Labs LLC	Step down subsidiary			
2	Alembic Global Holding SA (AGH)*		Subsidiary	Consolidated	Yes	No
	а.	Alembic Pharmaceuticals Australia Pty Ltd	Step down subsidiary			
	b.	Alembic Pharmaceuticals Canada Ltd	Step down subsidiary			
	c.	Alembic Pharmaceuticals Europe Limited	Step down subsidiary			
	d.	Alnova Pharmaceuticals SA	Step down subsidiary			
	e.	Genius LLC*	Step down subsidiary			
	f.	Rhizen Pharmaceuticals AG	Associate of AGH		1	
	g.	Dahlia Therapeutics SA	Associate as a subsidiary of Rhizen Pharmaceuticals AG			
	h.	Rhizen Pharmaceuticals Inc. **	Associate as a subsidiary of Rhizen Pharmaceuticals AG			
	i.	Alembic Mami SPA ***	Joint Venture			
	j.	SPH Sine Alembic (Shanghai) Pharmaceutical Technology Limited****	Joint Venture			
3	Alembic Pharmaceuticals SPA		Subsidiary	Standalone	Yes	No
4	Incozen Therapeutics Private Ltd		Associate	Standalone	Yes	No



Conversel instal Linking Formanning (LLFOR AND 2171) w. o. f. [uns 7, 2023 break KC Meles & Co. O'me Reg. No. 07/94110800] Regid Office: Meghdhanush, Race Course, Vadedara - 350 007 [Branches: Ahmedahad - Bengaluru - Mumbal Phone: - 912 465 244000 [-email: councet@homedahcom | webaits: www.kcmedhad.com *Genius LLC is based out in Ukraine. The investment value in Genius LLC is already provided for by AGH during the previous year. As at September 30, 2023, Genius LLC does not have any asset/liability and no transaction is entered during the current quarter/period. Formal legal process for liquidation is yet to be initiated by the Parent Company.

K C Mehta & Co LLP

** The entity is dissolved during the previous year. The Parent Company has written off the investments during March 2023 quarter.

*** The consolidated unaudited financial results do not include share of profit or loss as the financial statements of the same have not been received or prepared by the Alembic Global Holdings SA and no further share of loss is required to borne by the Groups as the entire Equity capital and loan given to it is fully prododed for in earlier year. Formal legal process for dis-association is still to be initiated by the Parent Company.

**** The consolidated unaudited financial results do not include share of profit or loss in respect of a joint venture, agreement of which was entered into on May 7, 2019. We are informed that the Group has invested Rs. 0.46 Corores and the operations have not started till September 30, 2023 and therefore, there are no transactions for the quarter/period.



INDEPENDENT AUDITORS' REVIEW REPORT ON THE STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED ON SEPTEMBER 30, 2023

K C Mehta & Co LLP

The Board of Directors Alembic Pharmaceuticals Limited

- We have reviewed the accompanying Statement of Standalone Unauded Financial Results of Adembic Pharmaceutical United (¹this Company¹) for the quarter and bull year ended systemethy 30, 2023 (¹this Statement²), being submitted by the Company pursuant to the requirements of Regulation 32 of the Statement is the responsibility of the Company³ Management and has been approved by the Board Of Directors. Our responsibility is of users a conduction on the Statement Based on un review.
- 2. We conducted our review of the Statement in accordance with the Standard on Review Engenments (SME) 2410 "Review of Interim Financial Information Fertimed by the Integratement Auditor of the TMT, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to calation in donating associations of India. This standard requires that we plan and perform the review to calation in donating associations of India. This standard requires that we plan and perform the review to calation in donating associations of India. This standard requires that we plan and perform the review to calation and associations and associations and associations and associations and addition.
- 3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanyle Statement, prepared in according with applicable bina Accounting Standards prescribed under section 13 of the Companie Act, 2013 read with relevant Rules and other recognized accounting partices and policities have, based to account the information required to be the companyle accounting partices and policy and the accounting accounting partices and policy and the accounting partices and policy and accounting the manner in which it is to be disclosed, or that to contain sym partice in indicational indication accounting accounting instances and other instances or which it is to be disclosed, or that to contain sym partice initial instances.

For K C Mehta & Co LLP Chartered Accountants Firm's Registration No. 106237W/W100829

Milin Mehta

Partner Membership No. 038665 UDIN: 23038665BHBXDA4944 Place: Vadodara Date: November 7, 2023



Converted into Linking Factorship ILLPIN ARX 51371) w.e.f. part 7,3822 from K.C.Meira & G., Olima Jag, Na: GUPALI28000 Regid Offices: Meghidhannush, Barce Course, Vadiodara - 360 0071 [Branchese: Ahmediabad - Biergalauru - Mumbail Phone: +91 265 2444000 [+ mail: connect/s@courseha.com] website: www.kemebha.com